KR930701601A - O-글리코실화 ifn-알파 - Google Patents
O-글리코실화 ifn-알파Info
- Publication number
- KR930701601A KR930701601A KR1019930700049A KR930700049A KR930701601A KR 930701601 A KR930701601 A KR 930701601A KR 1019930700049 A KR1019930700049 A KR 1019930700049A KR 930700049 A KR930700049 A KR 930700049A KR 930701601 A KR930701601 A KR 930701601A
- Authority
- KR
- South Korea
- Prior art keywords
- ifn
- interferon alpha
- glycosylated
- pad
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical class CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 claims abstract 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 8
- 102000006992 Interferon-alpha Human genes 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 5
- 239000013613 expression plasmid Substances 0.000 claims 5
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 238000001890 transfection Methods 0.000 claims 2
- 108091006033 O-glycosylated proteins Proteins 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000011097 chromatography purification Methods 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- QCQYVCMYGCHVMR-AAZUGDAUSA-N n-[(2r,3r,4s,5r)-4,5,6-trihydroxy-1-oxo-3-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical compound CC(=O)N[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QCQYVCMYGCHVMR-AAZUGDAUSA-N 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 230000006920 protein precipitation Effects 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 150000004044 tetrasaccharides Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 238000010276 construction Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904021917 DE4021917A1 (de) | 1990-07-10 | 1990-07-10 | Glykosyliertes ifnalpha |
| DEP4021917.8 | 1990-07-10 | ||
| DE19904035877 DE4035877A1 (de) | 1990-11-12 | 1990-11-12 | O-glycosyliertes ifn-alfa2 |
| DEP4035877.1 | 1990-11-12 | ||
| PCT/EP1991/001266 WO1992001055A1 (de) | 1990-07-10 | 1991-07-06 | O-glycosyliertes ifn-alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR930701601A true KR930701601A (ko) | 1993-06-12 |
Family
ID=25894855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019930700049A Withdrawn KR930701601A (ko) | 1990-07-10 | 1991-07-06 | O-글리코실화 ifn-알파 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0538300B1 (enExample) |
| JP (1) | JPH06502987A (enExample) |
| KR (1) | KR930701601A (enExample) |
| AT (1) | ATE104348T1 (enExample) |
| AU (1) | AU650893B2 (enExample) |
| CA (1) | CA2084514A1 (enExample) |
| CZ (1) | CZ386392A3 (enExample) |
| DE (1) | DE59101397D1 (enExample) |
| DK (1) | DK0538300T3 (enExample) |
| ES (1) | ES2063515T3 (enExample) |
| FI (1) | FI930058A7 (enExample) |
| HU (1) | HUT65846A (enExample) |
| NO (1) | NO930059D0 (enExample) |
| PL (1) | PL297610A1 (enExample) |
| SK (1) | SK386392A3 (enExample) |
| WO (1) | WO1992001055A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| NZ245771A (en) * | 1992-02-07 | 1994-08-26 | New England Medical Center Inc | Mammalian gastrin/cholecystokinin b (cck-b) receptor and antagonists |
| US5541071A (en) * | 1992-02-07 | 1996-07-30 | New England Medical Center Hospitals, Inc. | Assay for identifying antagonists of gastrin and CCK-B receptors |
| EP0626448A3 (de) * | 1993-05-26 | 1998-01-14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verfahren zur Herstellung und Reinigung von alpha-Interferon |
| CA2202148A1 (en) | 1994-10-28 | 1996-05-09 | Belinda Giesendorf | Polynucleic acid sequences for use in the detection and differentiation of prokaryotic organisms |
| WO1998006863A1 (en) * | 1996-08-14 | 1998-02-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A vector for polynucleotide vaccines |
| GB9904695D0 (en) * | 1999-03-01 | 1999-04-21 | Imp Cancer Res Tech | Peptide |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2292273A3 (en) * | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodeling and glycoconjugation of peptides |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2841097A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
| AU2004221824B2 (en) | 2003-03-14 | 2009-08-27 | Ratiopharm Gmbh | Branched water-soluble polymers and their conjugates |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| CA2522345A1 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| NZ548123A (en) | 2004-01-08 | 2010-05-28 | Novo Nordisk As | O-linked glycosylation of peptides |
| WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| CA2593682C (en) | 2005-01-10 | 2016-03-22 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
| US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| US20080255026A1 (en) | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| AR078117A1 (es) | 2006-06-20 | 2011-10-19 | Protech Pharma S A | Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina |
| CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
| EP2144923B1 (en) | 2007-04-03 | 2013-02-13 | BioGeneriX AG | Methods of treatment using glycopegylated g-csf |
| WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
| WO2014102101A1 (en) | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Novel intron sequences |
| WO2014102103A2 (en) | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Heterologous intron within a signal peptide |
| RU2610173C1 (ru) * | 2016-03-30 | 2017-02-08 | Илья Александрович Марков | Рекомбинантная плазмида pFM-IFN-17, обеспечивающая экспрессию интерферона альфа-2b человека, рекомбинантная плазмида pFM-АР, обеспечивающая экспрессию фермента метионинаминопептидазы E. coli, биплазмидный штамм Escherichia coli FM-IFN-АР (pFM-IFN-17, pFM-АР) - продуцент (Met-) рекомбинантного интерферона альфа-2b человека |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN150740B (enExample) * | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
| EP0085693A1 (en) * | 1981-08-14 | 1983-08-17 | A/S Alfred Benzon | Subjects relating to human inteferon-alpha subtype proteins and corresponding antibodies |
| DE3306060A1 (de) * | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| FR2560212B1 (fr) * | 1984-02-24 | 1989-12-29 | Unicet | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps |
-
1991
- 1991-07-06 PL PL29761091A patent/PL297610A1/xx unknown
- 1991-07-06 ES ES91912306T patent/ES2063515T3/es not_active Expired - Lifetime
- 1991-07-06 HU HU9300036A patent/HUT65846A/hu unknown
- 1991-07-06 SK SK3863-92A patent/SK386392A3/sk unknown
- 1991-07-06 WO PCT/EP1991/001266 patent/WO1992001055A1/de not_active Ceased
- 1991-07-06 FI FI930058A patent/FI930058A7/fi not_active Application Discontinuation
- 1991-07-06 JP JP3511638A patent/JPH06502987A/ja active Pending
- 1991-07-06 AT AT91912306T patent/ATE104348T1/de not_active IP Right Cessation
- 1991-07-06 KR KR1019930700049A patent/KR930701601A/ko not_active Withdrawn
- 1991-07-06 EP EP91912306A patent/EP0538300B1/de not_active Expired - Lifetime
- 1991-07-06 CA CA002084514A patent/CA2084514A1/en not_active Abandoned
- 1991-07-06 DK DK91912306.7T patent/DK0538300T3/da active
- 1991-07-06 DE DE59101397T patent/DE59101397D1/de not_active Expired - Fee Related
- 1991-07-06 AU AU82082/91A patent/AU650893B2/en not_active Ceased
-
1992
- 1992-12-23 CZ CS923863A patent/CZ386392A3/cs unknown
-
1993
- 1993-01-08 NO NO930059A patent/NO930059D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK386392A3 (en) | 1994-08-10 |
| CZ386392A3 (en) | 1993-08-11 |
| NO930059L (no) | 1993-01-08 |
| JPH06502987A (ja) | 1994-04-07 |
| WO1992001055A1 (de) | 1992-01-23 |
| NO930059D0 (no) | 1993-01-08 |
| FI930058A0 (fi) | 1993-01-08 |
| AU8208291A (en) | 1992-02-04 |
| FI930058L (fi) | 1993-01-08 |
| EP0538300B1 (de) | 1994-04-13 |
| ES2063515T3 (es) | 1995-01-01 |
| DK0538300T3 (da) | 1994-10-10 |
| HUT65846A (en) | 1994-07-28 |
| CA2084514A1 (en) | 1992-01-11 |
| EP0538300A1 (de) | 1993-04-28 |
| ATE104348T1 (de) | 1994-04-15 |
| HU9300036D0 (en) | 1993-04-28 |
| AU650893B2 (en) | 1994-07-07 |
| FI930058A7 (fi) | 1993-01-08 |
| PL297610A1 (enExample) | 1992-07-13 |
| DE59101397D1 (de) | 1994-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2107728C1 (ru) | Способ получения человеческого иммунного интерферона | |
| Pestka | The human interferon α species and receptors | |
| Conrad et al. | Effect of B cell stimulatory factor-1 (interleukin 4) on Fc epsilon and Fc gamma receptor expression on murine B lymphocytes and B cell lines. | |
| EP0417563B1 (de) | TNF-bindende Proteine | |
| Gray et al. | Expression of human immune interferon cDNA in E. coli and monkey cells | |
| US5503828A (en) | Alpha interferon composition and method for its production from human peripheral blood leukocytes | |
| US5723121A (en) | Sugar modified interferon | |
| DE69520088T3 (de) | Interferon-gamma-induzierendes Polypeptid monoklonal Antikörper, und Zusammensetzung für Interferon-gamma gebunden Krankheiten | |
| Loughnan et al. | T-cell-replacing factor (interleukin 5) induces expression of interleukin 2 receptors on murine splenic B cells. | |
| DE69131426T2 (de) | Neue wasserlösliche polypeptide mit hoher affinität für alpha- und beta- interferone | |
| EP0271824A2 (de) | Pferde-Gamma-Interferon | |
| DE3587669T2 (de) | Menschliche IL-1-cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren. | |
| US6319691B1 (en) | Fusion proteins comprising IFN-alpha2b and TM-alpha1 | |
| EP0553667B1 (en) | Soluble LDL receptor, its production and use | |
| US6365713B1 (en) | Soluble LDL receptor, its production and use | |
| KR920012440A (ko) | 인간 인터류킨-5 수용체 | |
| DE3306060A1 (de) | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung | |
| DE69332576T2 (de) | Glykolisierte Cytokine | |
| DE3515336C2 (de) | Verfahren zur Herstellung und Reinigung von â-Interferon | |
| Havell | Isolation of a subspecies of murine interferon antigenically related to human leukocyte interferon | |
| Alkan et al. | Antiviral and antiproliferative effects of interferons delivered via monoclonal antibodies | |
| US20030017550A1 (en) | DNA sequences encoding fusion proteins comprising IFN-beta and TM-alpha1 | |
| US5427781A (en) | Method of activating T cells with lymphokine SAF | |
| WO2000006596A2 (en) | INTERFERON-alpha HYBRIDS | |
| US6685933B1 (en) | Interferon α hybrids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19930108 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |